Analyst Price Targets — CVRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 12:18 pm | — | Cantor Fitzgerald | $5.00 | $2.96 | TheFly | CVRx price target lowered to $5 from $13 at Cantor Fitzgerald |
| August 7, 2026 12:05 pm | Frank Takkinen | Lake Street | $3.50 | $2.73 | TheFly | CVRx downgraded to Hold from Buy at Lake Street |
| August 7, 2026 11:27 am | — | Craig-Hallum | $4.00 | $5.94 | TheFly | CVRx downgraded to Hold from Buy at Craig-Hallum |
| August 7, 2026 6:08 am | — | Piper Sandler | $4.00 | $5.94 | StreetInsider | Piper Sandler Downgrades CVRx Inc (CVRX) to Neutral |
| February 13, 2026 11:53 am | William Plovanic | Canaccord Genuity | $10.00 | $5.69 | TheFly | CVRx price target lowered to $10 from $11 at Canaccord |
| November 6, 2025 1:45 pm | Ross Osborn | Cantor Fitzgerald | $13.00 | $9.98 | TheFly | CVRx price target raised to $13 from $11 at Cantor Fitzgerald |
| October 30, 2024 7:55 am | Matt O'Brien | Piper Sandler | $16.00 | $12.90 | StreetInsider | CVRx Inc (CVRX) PT Raised to $16 at Piper Sandler |
| September 10, 2024 7:48 am | Ross Osborn | Cantor Fitzgerald | $14.00 | $7.96 | TheFly | Cantor starts CVRx with Overweight on heart failure potential |
| July 30, 2024 6:51 am | Matt O'Brien | Piper Sandler | $13.00 | $9.27 | TheFly | CVRx price target lowered to $13 from $15 at Piper Sandler |
| July 30, 2024 6:27 am | William Plovanic | Canaccord Genuity | $15.00 | $9.27 | StreetInsider | CVRx Inc (CVRX) PT Raised to $15 at Canaccord Genuity |
Latest News for CVRX
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX).
CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.
On Behalf of Investors of CVRx, Inc. - CVRX NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the…
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
No House trades found for CVRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.